EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study

Hiromi Tomono iD, Hirokazu Taniguchi iD, Minoru Fukuda iD, Takaya Ikeda, Seiji Nagashima, Kazumasa Akagi, Sawana Ono, Yasuhiro Umeyama, Midori Shimada, Hiroshi Gyotoku, Shinnosuke Takemoto iD, Yasushi Hisamatsu und 11 weitere

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15097 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Hiromi Tomono und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Combined treatment using anti‐programmed death‐ligand 1 antibody (anti‐PD‐L1) and platinum‐etoposide is the current standard first‐line treatment for patients with extensive‐stage (ES) small cell lung cancer (SCLC). However, the best treatment for relapsed ES‐SCLC after the first‐line treatment remains unclear. There are some approved chemotherapeutic agents that can be used against ES‐SCLC, and treatment with irinotecan is well established as both a monotherapy and a combined therapy, in combination with platinum. Therefore, we conduct a phase II study with irinotecan in the second‐ or later‐line setting for patients with ES‐SCLC who have been previously treated with combined treatment.

Methods

Our study will enroll total 30 patients who are diagnosed with ES‐SCLC and have experienced disease progression after the combined treatment. Patients will receive irinotecan on days 1, 8, and 15, which will be repeated every 4 weeks. Doses of irinotecan (100/80/60 mg/m 2 ) will be determined according to the type of UGT1A1 gene polymorphism, and the treatment will be discontinued following disease progression, intolerance, withdrawal of patient consent, and based on the investigator's decision. The primary endpoint of the study is the response rate, and the secondary endpoints are overall survival, progression‐free survival, and safety.

Discussion

Since the present first‐line treatment has been changed to the combined treatment, the second‐ or later‐line treatment should be re‐evaluated for patients with relapsed SCLC. Irinotecan is a major chemotherapeutic agent used for SCLC. This study demonstrates and re‐evaluates the clinical benefits of irinotecan after combined treatment with anti‐PD‐L1 and platinum‐etoposide for patients with ES‐SCLC. Registration details This study was registered in the Japan Registry of Clinical Trials (no. jRCT s071210090) on November 4, 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsHumansIrinotecanEtoposidePlatinumCisplatinCamptothecinAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalImmunotherapyDisease ProgressionClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

combined chemo-immunotherapyirinotecansmall cell lung cancer

Substanzen

IrinotecanEtoposidePlatinumCisplatinCamptothecin

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
  • Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Respiratory Medicine, Nagasaki Prefecture Shimabara Hospital, Nagasaki, Japan.
  • Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.
  • Department of Thoracic Medical Oncology, Oita Prefectural Hospital, Oita, Japan.

ORCID-Profile: Hiromi Tomono, Hirokazu Taniguchi, Minoru Fukuda, Shinnosuke Takemoto, Hiroshi Soda

Zitieren

APA

Tomono, H., Taniguchi, H., Fukuda, M., Ikeda, T., Nagashima, S., Akagi, K., Ono, S., Umeyama, Y., Shimada, M., Gyotoku, H., Takemoto, S., Hisamatsu, Y., Morinaga, R., Tagawa, R., Ogata, R., Dotsu, Y., Senju, H., Soda, H., Nakatomi, K., …, & Mukae, H. (2023). Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15097

Vancouver

Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, et al. Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15097

BibTeX
@article{Tomono2023,
  author = {Tomono, Hiromi and Taniguchi, Hirokazu and Fukuda, Minoru and Ikeda, Takaya and Nagashima, Seiji and Akagi, Kazumasa and Ono, Sawana and Umeyama, Yasuhiro and Shimada, Midori and Gyotoku, Hiroshi and Takemoto, Shinnosuke and Hisamatsu, Yasushi and Morinaga, Ryotaro and Tagawa, Ryuta and Ogata, Ryosuke and Dotsu, Yosuke and Senju, Hiroaki and Soda, Hiroshi and Nakatomi, Katsumi and Hayashi, Fumiko and Sugasaki, Nanae and Kinoshita, Akitoshi and Mukae, Hiroshi},
  title = {Phase II study of IRInotecan treatment after COmbined chemo‐immunotherapy for extensive‐stage small cell lung cancer: Protocol of IRICO study},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15097}
}
Kostenlos starten →